Clinical outcomes with thin versus thick strut polymer-free biolimus-coated stents at 3 years.

ABSTRACT:

Background

For high bleeding-risk patients (HBR) undergoing percutaneous coronary intervention (PCI), the LEADERS FREE (LF) and LEADERS FREE II (LF II) trials established the safety and efficacy of a stainless steel polymer-free biolimus-coated stent (SS-BCS) with 30 days of dual antiplatelet treatment (DAPT). The LEADERS FREE III (LF III) trial investigated clinical outcomes after PCI with the next-generation cobalt-chromium thin-strut polymer-free biolimus-coated stent (CoCr-BCS) in HBR patients.

Aims

To report the final 3-year results of the LF III trial and compare them to LF II.

Methods

LF III was a prospective, multicentre, open-label single-arm study to evaluate the safety and efficacy of the CoCr-BCS stent. The primary safety endpoint was the composite of card

SUBMITTER: Eberli FR 

PROVIDER: S-EPMC11191790 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature